Assembly Biosciences, Inc. (ASMB) — Financial statements
Income statement, balance sheet, and cash flow for Assembly Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 72↑153.5% | 29↑298.2% | 7 | 0.00↓100.0% | 6 | |
| Cost of Revenue | 0.13 | 0.00↓100.0% | 49↓29.2% | 69 | 0.00 | |
| Gross Profit | 72↑153.1% | 29↑168.3% | -42↑39.6% | -69↓1204.6% | 6 | |
| Operating Expenses | ||||||
| R&D Expenses | 65↑15.9% | 56↑14.4% | 49↓30.1% | 70↑2.1% | 69 | |
| General & Administrative Expenses | 20↑8.9% | 18↓21.4% | 23↓4.3% | 24↓16.8% | 29 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 20↑8.9% | 18↓21.4% | 23↓4.3% | 24↓16.8% | 29 | |
| Other Expenses | 0.00 | 0.00↑100.0% | -49↑29.0% | -69↓265.4% | 42 | |
| Operating Expenses | 84↑14.2% | 74↑222.8% | 23↓8.5% | 25↓82.0% | 139 | |
| Total Costs & Expenses | 84↑14.2% | 74↑3.0% | 72↓23.7% | 94↓32.3% | 139 | |
| Operating Results | ||||||
| Operating Income | -12↑73.3% | -45↑29.7% | -65↑31.3% | -94↑29.1% | -133 | |
| Depreciation & Amortization | 0.13↑0.0% | 0.13↓71.3% | 0.45↓9.6% | 0.50↑6.9% | 0.47 | |
| EBITDA | -12↑73.5% | -45↑29.4% | -64↑30.6% | -93↓2.1% | -91 | |
| EBIT | -12↑73.3% | -45↑29.7% | -65↑30.5% | -93↓2.2% | -91 | |
| Interest & Other Income | ||||||
| Net Interest Income | 6↑7.6% | 6↑61.5% | 3↑237.7% | 1↑238.4% | 0.30 | |
| Interest Income | 6↑7.6% | 6↑61.5% | 3↑237.7% | 1↑238.4% | 0.30 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00↑100.0% | -1↑97.4% | -42 | |
| Other Income / Expenses | 6↑7.6% | 6↑61.5% | 3↑237.7% | 1↑238.4% | 0.30 | |
| Income Before Tax | -6↑84.6% | -40↑34.9% | -61↑34.3% | -93↑29.7% | -132 | |
| Income Tax Expense | 0.00↓100.0% | 0.33↑900.0% | 0.03 | 0.00↑100.0% | -3 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -6↑84.8% | -40↑34.4% | -61↑34.2% | -93↑28.3% | -130 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -6↑84.8% | -40↑34.4% | -61↑34.2% | -93↑28.3% | -130 | |
| Bottom-Line Net Income | -6↑84.8% | -40↑34.4% | -61↑34.2% | -93↑28.3% | -130 | |
| EPS (Basic) | -0.55↑91.8% | -6.69↑50.0% | -13.38↑41.4% | -22.82↑36.6% | -36.00 | |
| EPS (Diluted) | -0.55↑91.8% | -6.69↑50.0% | -13.38↑41.4% | -22.82↑36.6% | -36.00 | |
| Weighted Average Shares | 11↑86.7% | 6↑31.2% | 5↑13.5% | 4↑11.9% | 4 | |
| Weighted Average Diluted Shares | 11↑86.7% | 6↑31.2% | 5↑13.5% | 4↑11.9% | 4 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.